CORONADO BIOSCIENCES INC (CNDO)
(Delayed Data from NSDQ)
$3.44 USD
-0.53 (-13.35%)
Updated Apr 27, 2015 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Fortress Biotech, Inc. [CNDO]
Reports for Purchase
Showing records 1 - 20 ( 85 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for CNDO
Provider: ValuEngine, Inc
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Holding Pattern and Cash Heavy; Maintain Neutral; Target to $1.70
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE: The Week Ahead in Life Sciences - Upcoming Events for the Week of March 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
TRUST-II Fails; No Surprise Here; Maintain Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Q3:13 Update - CNDO''s Current Valuation Provides Free Call on Re-Analysis of TSO Data and Trust-II Read-Out by YE:13
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q13 Results; State of Limbo; Target Reduced to $1.60
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Our Speculation Misses; Remove from Focus List; Rating to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Weakness Creates a More Favorable Risk-Reward Scenario - Data Late Oct/Early Nov. - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
MID DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Initiation of TSO Phase II in UC- Phase II Crohn''s Data Anticipated in Oct./Nov. - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
TSO Program Expands; Critical Catalysts Soon; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L